Literature DB >> 23106931

Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.

Laura F McNicholas1, Amber M Holbrook, Kevin E O'Grady, Hendrée E Jones, Mara G Coyle, Peter R Martin, Sarah H Heil, Susan M Stine, Karol Kaltenbach.   

Abstract

AIM: To examine hepatic enzyme test results throughout the course of pregnancy in women maintained on methadone or buprenorphine.
DESIGN: Participants were randomized to either methadone or buprenorphine maintenance. Blood chemistry tests, including liver transaminases and hepatitis C virus (HCV) status, were determined every 4 weeks and once postpartum. As part of a planned secondary analysis, generalized mixed linear models were conducted with aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) as the dependent variables.
SETTING: Six US sites and one European site that provided comprehensive treatment to pregnant opioid-dependent women. PARTICIPANTS: A total of 175 opioid-dependent pregnant women enrolled in the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study.
FINDINGS: ALT, AST and GGT levels decreased for all subjects across pregnancy trimesters, rising slightly postpartum. HCV-positive subjects exhibited higher transaminases at all time-points compared to HCV-negative subjects, regardless of medication (all Ps < 0.05) condition. Both HCV-positive and negative buprenorphine-maintained participants exhibited lower GGT levels than those who were methadone-maintained (P < 0.05).
CONCLUSIONS: Neither methadone nor buprenorphine appear to have adverse hepatic effects in the treatment of pregnant opioid-dependent women.
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23106931      PMCID: PMC4268861          DOI: 10.1111/j.1360-0443.2012.04043.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  24 in total

1.  Seroprevalence of hepatitis C in a sample of middle class substance abusers.

Authors:  H D Abraham; S Degli-Esposti; L Marino
Journal:  J Addict Dis       Date:  1999

2.  Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine.

Authors:  N M Petry; W K Bickel; D Piasecki; L A Marsch; G J Badger
Journal:  Am J Addict       Date:  2000

3.  Pregnancy outcome in women who use opiates.

Authors:  O Fajemirokun-Odudeyi; C Sinha; S Tutty; P Pairaudeau; D Armstrong; T Phillips; S W Lindow
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-10-03       Impact factor: 2.435

4.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

5.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Authors:  Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

6.  Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.

Authors:  Gabriele Fischer; Romana Ortner; Klaudia Rohrmeister; Reinhold Jagsch; Andjela Baewert; Martin Langer; Harald Aschauer
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

7.  Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation.

Authors:  A Berson; D Fau; R Fornacciari; P Degove-Goddard; A Sutton; V Descatoire; D Haouzi; P Lettéron; A Moreau; G Feldmann; D Pessayre
Journal:  J Hepatol       Date:  2001-02       Impact factor: 25.083

8.  Hepatitis after intravenous buprenorphine misuse in heroin addicts.

Authors:  A Berson; A Gervais; D Cazals; N Boyer; F Durand; J Bernuau; P Marcellin; C Degott; D Valla; D Pessayre
Journal:  J Hepatol       Date:  2001-02       Impact factor: 25.083

9.  Acute liver and renal failure during treatment with buprenorphine at therapeutic dose.

Authors:  M Zuin; A Giorgini; C Selmi; P M Battezzati; C A Cocchi; A Crosignani; A Benetti; P Invernizzi; M Podda
Journal:  Dig Liver Dis       Date:  2008-02-21       Impact factor: 4.088

Review 10.  Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned.

Authors:  Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

View more
  7 in total

1.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 3.  Methadone and buprenorphine for the management of opioid dependence in pregnancy.

Authors:  Hendrée E Jones; Loretta P Finnegan; Karol Kaltenbach
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

4.  Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study.

Authors:  Elizabeth E Krans; Susan L Zickmund; Vinod K Rustgi; Seo Young Park; Shannon L Dunn; Eleanor B Schwarz
Journal:  Subst Abus       Date:  2015-11-16       Impact factor: 3.716

5.  Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.

Authors:  Uma M Reddy; Jonathan M Davis; Zhaoxia Ren; Michael F Greene
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.623

Review 6.  New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Authors:  Michael Soyka
Journal:  Subst Abuse Rehabil       Date:  2015-01-06

7.  Histopathological study of liver tissue due to methadone consumption and its effect on liver enzymes and inflammatory indices in rat.

Authors:  Mansour Amraei; Mahmoud Mohamadpour; Mohammad Reza Hafezi Ahmadi; Monireh Azizi; Ahmad Daemi; Mohammad Omidi; Ehsan Shirzadpour
Journal:  Drug Des Devel Ther       Date:  2018-11-05       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.